Core Viewpoint - Aibo Medical (688050) is planning to acquire at least 51% of the shares of Demei Medical, aiming to gain control over the company, which is a leading player in the domestic sports medicine sector [1] Company Announcement Summary - Aibo Medical signed a letter of intent on January 20, 2026, with Demei United (Chongqing) Medical Technology Co., Ltd. and its founder Li Jianbo to acquire at least 51% of Demei Medical's shares through a combination of acquisition loans and self-funding [1] - Demei Medical is recognized as a national high-tech enterprise and a "specialized, refined, and innovative" small giant enterprise, holding 276 patents and covering the entire chain from preoperative prevention to surgical treatment and postoperative rehabilitation [1] - The transaction is subject to due diligence, formal agreement signing, and internal approval processes, and currently serves as a preliminary intention without legal binding force, except for confidentiality and exclusivity clauses [1]

Core Viewpoint - Aibo Medical announced that by the end of June 2025, the company expects to have nearly 300 research and development personnel [2] Group 1 - The company is actively expanding its R&D team to enhance its capabilities [2] - Information regarding the compensation of board members will be disclosed in the company's regular reports [2]

Group 1 - The core viewpoint of the article is that Aibo Medical has confirmed normal management of accounts receivable and no equity pledge risk for its major shareholder [1] Group 2 - As of the current date, the company states that its accounts receivable management is functioning normally [1] - The major shareholder of the company has no equity pledge situation [1] - There is no existence of pledge risk associated with the company's major shareholder [1]

Core Viewpoint - Aibo Medical has been actively selling its artificial lens products in various EU countries since their launch, indicating a successful market penetration strategy [1]. Group 1 - The company has reported that its artificial lens products are being sold in Germany, France, Italy, and other EU countries and regions [1]. - Investors are encouraged to refer to the company's regular reports for more detailed information regarding sales and market performance [1].

Core Viewpoint - The company acknowledges the widespread application of AI technology across various industries and plans to actively promote its use in research, production, and sales based on industry characteristics and the company's actual situation [1] Group 1 - The company is aware of the extensive use of AI technology in different sectors [1] - The company intends to leverage AI technology in its operations [1] - The application of AI will be tailored to the specific characteristics of the industry and the company's circumstances [1]

Group 1 - The core viewpoint of the article highlights that Aibo Medical's Longjing PR product is leading in the domestic market, breaking the monopoly of imported products in its field due to its excellent optical performance, good biocompatibility, and diverse model adaptations [1]

Group 1 - The core viewpoint of the article is that Aibo Medical is considering expanding its product line beyond ophthalmology by leveraging its technological advantages in medical materials [2] Group 2 - Aibo Medical has indicated that it does not rule out future developments in other fields apart from ophthalmology [2]

Group 1 - The core viewpoint of the article is that Aibo Medical has confirmed that its major shareholder has not engaged in any illegal reduction of holdings [2] Group 2 - Aibo Medical responded to investor inquiries on its interactive platform [2] - The company aims to maintain transparency regarding its shareholder activities [2]

Group 1 - The core viewpoint of the article highlights that Aibo Medical's Longjing® PR product is leading in the domestic market, breaking the monopoly of imported products in its field due to its excellent optical performance, good biocompatibility, and diverse model adaptations [2] Group 2 - Aibo Medical responded to investor inquiries on an interactive platform, emphasizing the competitive advantages of its Longjing® PR product [2] - The product's attributes are positioned as superior to those of imported alternatives, indicating a significant shift in market dynamics [2] - The company aims to establish a strong foothold in the domestic market by leveraging its innovative product features [2]

Core Viewpoint - Aibo Medical has committed to strictly adhere to information disclosure regulations and will announce relevant information promptly if it meets the performance forecast standards for the Sci-Tech Innovation Board [2] Group 1 - The company responded to investor inquiries on its interactive platform [2] - Aibo Medical emphasized its compliance with legal requirements regarding information disclosure [2] - The company will issue timely announcements if it reaches the performance forecast criteria [2]